-

Schrödinger to Present at Jefferies Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference. The live presentation will take place on Wednesday, June 5, 2024, at 2:30 p.m. ET.

The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.

Founded in 1990, Schrödinger has approximately 850 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.

Contacts

Allie Nicodemo
Schrödinger, Inc.
allie.nicodemo@schrodinger.com
617-356-2325

Schrödinger

NASDAQ:SDGR

Release Summary
Schrödinger today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference.
Release Versions

Contacts

Allie Nicodemo
Schrödinger, Inc.
allie.nicodemo@schrodinger.com
617-356-2325

Social Media Profiles
More News From Schrödinger

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

MILAN--(BUSINESS WIRE)--Schrödinger announces encouraging initial clinical data from its ongoing Phase 1 dose-escalation study of SGR-1505....

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the grant of inducement equity awards to the company’s newly appointed EVP, Chief Commercial Officer, Global Head of Software Sales & Marketing, Mannix Aklian. As previously announced, Mr. Aklian joined the company on May 28, 2025. The grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a deleg...

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will have global oversight of Schrödinger’s account management teams and will be responsibl...
Back to Newsroom